Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments.
Opinion Statement: Bronchial carcinoids are uncommon tumors accounting for 20 to 30% of all neuroendocrine tumors and about 1-2% of all cancers of pulmonary origin. Bronchial carcinoids are well-differentiated neuroendocrine tumors and have a favorable survival outcome when compared with other subty...
| Publicado en: | Current Treatment Options in Oncology Vol. 21; no. 11; pp. 1 - 20 |
|---|---|
| Autores principales: | , , , |
| Formato: | review Journal Article |
| Publicado: |
Springer Nature
Nov2020
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=146431599&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 146431599 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 15272729 3KHC jtl: Current Treatment Options in Oncology issn: 15272729 maglogo: N pubinfo: dt: Nov2020 vid: 21 iid: 11 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 146431599 146431599 NLM32862320 146431599 10.1007/s11864-020-00786-0 NLM32862320 146431599 ppf: 1 ppct: 19 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Pulmonary Neuroendocrine Tumors: Adjuvant and Systemic Treatments. aug: au: Uprety, Dipesh Halfdanarson, Thorvardur R. Molina, Julian R Leventakos, Konstantinos affil: Division of Medical Oncology, Mayo Clinic, 200 First St SW, 55905, Rochester, MN, USA sug: ab: Opinion Statement: Bronchial carcinoids are uncommon tumors accounting for 20 to 30% of all neuroendocrine tumors and about 1-2% of all cancers of pulmonary origin. Bronchial carcinoids are well-differentiated neuroendocrine tumors and have a favorable survival outcome when compared with other subtypes of lung cancers. Treatment of bronchial carcinoids is not simple owing to intricacy of symptom presentation and heterogeneity of disease biology. Successful treatment of patients requires a multimodality approach. Resection is curative in the majority of patients with localized tumors and adjuvant treatment is not routinely recommended. Multiple options for systemic therapy exist for patients with advanced disease. To date, very few randomized clinical trials have been done, partly owing to the relative rarity of this malignancy. Somatostatin analogs (SSAs) are reasonable first-line choice for patients with tumors expressing somatostatin receptors. Everolimus is an appropriate first-line choice for somatostatin receptor negative tumors and for any patients with progressive disease. PRRT can also be considered for progressive tumors expressing somatostatin receptors. Based on retrospective series, cytotoxic chemotherapy can be selected in patients with progressive tumors, primarily when cytoreduction is needed. Herein, we will discuss evidence supporting the role of adjuvant and systemic treatment therapies for those with bronchial carcinoid tumors by focusing on various studies. pubtype: Academic Journal doctype: review Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|